Poor Control of Celiac Disease Increases Lymphoma Risk

Share this content:
Follow-Up Biopsies in Celiac Disease Help ID Lymphoma Risk
Follow-Up Biopsies in Celiac Disease Help ID Lymphoma Risk

(HealthDay News) -- Patients with celiac disease (CD) who have intestinal biopsy showing persistent villous atrophy are at increased risk for lymphoproliferative malignancy (LPM), according to research published in the Aug. 6 issue of the Annals of Internal Medicine.

Benjamin Lebwohl, M.D., of the Columbia University College of Physicians and Surgeons in New York City, and colleagues conducted a population-based cohort study to assess the association between mucosal healing or damage on intestinal biopsy in CD and risk for LPM.

The researchers found that, of 7,625 patients with CD who had follow-up intestinal biopsy after initial diagnosis, 3,308 patients (43%) had persistent villous atrophy. Patients with persistent villous atrophy had a higher rate of LPM (standardized incidence ratio [SIR], 3.78) than those with mucosal healing (SIR, 1.50) or that expected in the general population (SIR, 2.81).

Compared with those with mucosal healing, CD patients with persistent villous atrophy were at increased risk for LPM (hazard ratio [HR], 2.26).

"Follow-up biopsies may be useful in identifying patients with CD at increased risk for LPM," the authors write.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs